Know Cancer

or
forgot password

Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study


N/A
18 Years
N/A
Open (Enrolling)
Both
OMS Grade II Glioma

Thank you

Trial Information

Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study


Inclusion Criteria:



- OMS grade II glioma

- signed informed consent

- age >=18

- IK >=80%

- ability to read, write and undertand French

Exclusion Criteria:

- glioma localized to brainstem

- other neurologic or psychiatric disease

- history of other malignancies, other than curatively treated in-situ carcinoma of the
cervix or basal cell carcinoma of the skin, or any other curatively treated cancer
with no sign of recurrence within 5 years prior to randomization

- neuroleptic concomitant treatment

- pregnant or lactating women

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MoCA test

Outcome Time Frame:

36 months

Safety Issue:

No

Principal Investigator

Marie-Pierre SUNYACH, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Léon Bérard, Lyon - FRANCE

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

TUMEURS GLIALES

NCT ID:

NCT01305122

Start Date:

February 2011

Completion Date:

February 2019

Related Keywords:

  • OMS Grade II Glioma
  • Glioma
  • Neurocognitive functions
  • Glioma

Name

Location